Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering

Dataset grows to more than 312,000 whole genomes with longitudinal clinical data GSK is one of the first to lead a further expansion of 50,000 whole genomes paired with proteomic data   SAN DIEGO, March 5, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC (NashBio), today announced two advancements in scale and depth of the Alliance for Genomic Discovery (AGD or the Alliance). With the addition of Regeneron Genetics Center® (RGC®) as the tenth member, the Alliance can expand the core dataset to 312,000 whole genomes.

PRNewsWire • 19 hours ago

Why Illumina (ILMN) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Mar 4, 2026

Illumina, Inc. (ILMN) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Illumina, Inc. (ILMN) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Seeking Alpha • Mar 4, 2026

Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida

Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Laboratory Services, Illumina's CLIA-certified laboratory, is providing clinical sequencing and interpretation services to the new Diagnostic Lab at Florida Institute for Pediatric Rare Diseases (IPRD) at Florida State University (FSU) College of Medicine, further driving innovation in diagnostics and treatments for rare diseases. "An estimated 30 million people across the country are living with a rare disease today and clinical whole-genome testing provides a transformative opportunity to end the diagnostic odyssey for patients," said Eric Green, MD, PhD, chief medical officer of Illumina.

PRNewsWire • Feb 27, 2026

Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026

SAN JOSE, Calif.--(BUSINESS WIRE)-- #NGS--Takara Bio USA collaborates with Illumina on a single-cell-resolution spatial mapping workflow, presented at AGBT 2026.

Business Wire • Feb 26, 2026

TEM vs. ILMN: Which MedTech Stock Offers Greater Upside?

In 2026, MedTech players' success will hinge on their ability to balance near-term pressure with long-term transformation. Per a report by ZS, these players must address immediate operational, financial, and regulatory challenges without losing sight of broader industry shifts.

Zacks Investment Research • Feb 26, 2026

Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics

At AGBT, researchers reveal new findings from studies leveraging Illumina's multiomics solutions SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing, and proteomics technologies. The ability to combine more than one omic insight reveals unprecedented biological depth and knowledge, all of which is streamlined by Illumina Connected Multiomics for multimodal data analysis.

PRNewsWire • Feb 25, 2026

Illumina launches TruPath Genome, setting a new standard in genomic insight

TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow Data presented at AGBT demonstrates TruPath Genome's accuracy in detecting rare genetic disease Broad Clinical Labs is among first to adopt product, which was previously known as "constellation mapped read technology" SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of TruPath™ Genome, setting a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver unparalleled accuracy and resolution—even across so-called "dark regions" of the genome—providing researchers with a more complete picture of genomic alterations implicated in genetic disease.

PRNewsWire • Feb 24, 2026

Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility

40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaS eq X systems , advancing precision medicine and delivering compounded value for NovaSeq X customers SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today unveiled an 18-month roadmap of innovations that enhance the power and value of the NovaSeq X system. Updates include technology that will deliver up to a Q70 quality score for the first time, along with 30% increased speed and output up to 35 billion reads (35B).

PRNewsWire • Feb 23, 2026

Why Illumina (ILMN) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Feb 18, 2026